Know Cancer

or
forgot password


Phase 1
18 Years
80 Years
Not Enrolling
Both
Myeloma

Thank you

Trial Information


Inclusion Criteria:



- Myeloma in remission

Exclusion Criteria:

- Adverse events (AEs) to statin, already on a statin, or contraindication to statin

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Andrew Spencer, MBChB, FRACP, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Alfred

Authority:

Australia: Department of Health and Ageing Therapeutic Goods Administration

Study ID:

7/04

NCT ID:

NCT00164086

Start Date:

Completion Date:

Related Keywords:

  • Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location